Prime Medicine assumed with a Buy at JonesResearch

JonesResearch assumed coverage of Prime Medicine with a Buy rating and $14 price target. The firm says Prime is “highly differentiated and is leading the pack” of prime editing tech companies, the only prime editing company in the clinic. A lack of double strand break gives prime editing an edge over crisper technology, and ability to perform all 12 possible nucleotide edits versus six with base editing puts them ahead of base editors, the analyst tells investors in a research note.